Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03952507 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Relative Oral Bioavailability and Food Effect of Single-dose of JNJ-64417184 in Healthy Participants
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT03952507 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 18 participants.
The verdict
NCT03952507, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the relative bioavailability of JNJ-64417184, formulated as a test formulation (tablet) compared to a reference formulation (suspension), administered orally in a fasted state, in healthy participants.
Interventions
- DRUG JNJ-64417184 600 (Oral Tablet Formulation)
- DRUG JNJ-64417184 (Oral Suspension Formulation)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-05-15 |
| Est. Completion | 2019-06-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03952507
The ClinicalTrials.gov registry entry for NCT03952507 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which JNJ-64417184 600 (Oral Tablet Formulation) is the first listed.
NCT03952507 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03952507 about?
NCT03952507 is a clinical study titled "A Study to Assess the Relative Oral Bioavailability and Food Effect of Single-dose of JNJ-64417184 in Healthy Participants". The main purpose of this study is to evaluate the relative bioavailability of JNJ-64417184, formulated as a test formulation (tablet) compared to a reference formulation (suspension), administered orally in a fasted state, in healthy participants.
What is the current status of trial NCT03952507?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2019-05-15. Estimated completion is 2019-06-22.
What interventions are being tested in trial NCT03952507?
The interventions under investigation include: JNJ-64417184 600 (Oral Tablet Formulation) (DRUG), JNJ-64417184 (Oral Suspension Formulation) (DRUG).
Who is sponsoring clinical trial NCT03952507?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.